Evaluation of Motexafin gadolinium (MGd) as a contrast agent for intraoperative MRI

Minimally Invasive Neurosurgery

Volumn 50, Issue 6, 2007, Pages 318-323

  Hirschberg, H ^a,c   Wu, G N ^b   Madsen, S J ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF NEVADA   (United States)

Author keywords

Intraoperative MRI; Motexafin; Rat brain tumor; Surgically induced contrast

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM TEXAPHYRIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN RADIOGRAPHY; BRAIN TUMOR; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DETERIORATION; FEMALE; INTERVENTIONAL MAGNETIC RESONANCE IMAGING; LETHARGY; MALE; MENINX; MOTOR PERFORMANCE; NONHUMAN; RAT; TIME; TUMOR NECROSIS;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CELL LINE, TUMOR; CEREBROVASCULAR CIRCULATION; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; ENCEPHALITIS; FEMALE; GLIOMA; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MALE; METABOLIC CLEARANCE RATE; METALLOPORPHYRINS; MONITORING, INTRAOPERATIVE; PHOTIC STIMULATION; PHOTOCHEMOTHERAPY; PREDICTIVE VALUE OF TESTS; RATS; RATS, INBRED F344;

EID: 39149131672     PISSN: 09467211     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-993158     Document Type: Article

References (38)

1. Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 1994; 34: 45-61
2. Yoshida J, Kajita Y, Wakabayashi T et al. Long-term follow-up results of 175 patients with malignant glioma: importance of radical tumour resection and postoperative adjuvant therapy with interferon, ACNU and radiation. Acta Neurochir 1994; 127: 55-59
3. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, De Monte F, Lang FF, MacCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D, Sawaya R. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001; 95: 190-198
4. Stummer W, Pichlmeier U, Meinel T, Wiestler O, Zanella F, Reulen H. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006; 7: 392-401
5. Hirschberg H, Samset E, Hole PK, Lote K. Impact of intraoperative MRI on the results of surgery for high grade gliomas. Minim Invas Neurosurg 2005; 48: 77-84
6. Wirtz CR, Knauth M, Staubert A, Bonsanto MM, Sartor K, Kunze S, Tronnier VM. Clinical evaluation and follow-up results for intraoperative magnetic resonance imaging in neurosurgery. Neurosurgery 2000; 46: 1112-1120
7. Lunsford LD, Kondziolka D, Bissonette DJ. Intraoperative imaging of the brain. Stereotact Funct Neurosurg 1996; 66: 58-64
8. Hammoud MA, Ligon BL, el Souki R et al. Use of intraoperative ultrasound for localizing tumors and determining the extent of resection. A comparative study with magnetic resonance imaging. J Neurosurg 1996; 84: 737-774
9. Hirschberg H, Unsgaard G. Incorporation of ultrasonic imaging in an optically coupled frameless stereotatic system. Acta Neurochirurgica 1997; 68: 75-80
10. Gronningsaeter A, Kleven A, Ommedal S, Aarseth TE, Lie T, Lindseth F, Lango T, Unsgard G. SonoWand, an ultrasound-based neuronavigation system. Neurosurgery 2000; 47: 1373-1379
11. Hirschberg H, Samset E. Intraoperative image directed dye marking of tumor margins. Minim Invas Neurosurg 1999; 42: 123-127
12. Dietrich J, Schneider JP, Schulz T et al. Intraoperative appearance of the resection area in brain-tumor operations in an open 0.5 MRT. Radiologe 1998; 38: 935-942
13. Knauth M, Aras N, Wirtz CR et al. Surgically induced intracranial contrast enhancement. Potential source of error in intraoperative MRI. AJNR Am J Neuroradiol 1999; 20: 1547-1553
14. Knauth M, Egelhof T, Roth SU, Wirtz CR, Sartor K. Monocrystalline iron oxide nanoparticles: possible solution to the problem of surgically induced intracranial contrast enhancement in intraoperative MR imaging. AJNR Am J Neuroradiol 2001; 22: 99-102
15. Varallyay P, Nesbit G, Muldoon LL, Nixon RR, Delashaw J, Cohen JI, Petrillo A, Rink D, Neuwelt EA. Comparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging intracranial tumors. AJNR Am J Neuroradiol 2002; 23: 510-519
16. Kircher MF, Mahmood U, King RS, Weissleder R, Josephson L. A multi-modal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Research 2003; 63: 8122-8125
17. Sessler JL, Murai T, Hemmi G. A water-stable gadolinium(III) complex derived from a new pentadentate expanded porphyrin ligand. Inorg Chem 1989; 28: 3390-3393
18. Sessler JL, Burrell AK. Expanded porphyrins. Top Curr Chem 1992; 161: 177-273
19. Young SW, Qing F, Harriman A et al. Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI. Proc Natl Acad Sci USA 1996; 93: 6610-6615
20. Sessler JL, Mody TD, Hemmi GW et al. Gadolinium(III) texaphyrin: a novel MRI contrast agent. J Am Chem Soc 1993; 115: 10368-10369
21. Young SW, Sidhu MK, Qing F et al. Preclinical evaluation of gadolinium(III) texaphyrin complex. Inv Radiol 1994; 29: 330-338
22. Wu GN, Ford JM, Alger JR. MRI measurement of the uptake and retention of motexafin gadolinium in glioblastoma multiforme and uninvolved normal human brain. J Neuro-Oncol 2006; 77: 95-103
23. Carde P, Timmerman R, Mehta MP et al. Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases. J Clin Oncol 2001; 19: 2074-2083
24. De Stasio G, Rajesh D, Ford JM et al. Motexafin-gadolinium taken up in vitro by at least 90% of glioblastoma cell nuclei. Clin Cancer Res 2006; 12: 206-213
25. Ko L, Koestner A, Wechsler W. Characterization of cell cycle and biological parameters of transplantable glioma cell lines and clones. Acta Neuropathol 1980; 51: 107
26. Goodman JH, MacGregor JM, Clendenon NR, Gahbauer RA, Barth RF, Soloway AH, Fairchild RG. Inhibition of tumor growth in a glioma model treated with boron neutron capture therapy. Neurosurgery 1990; 27: 383
27. Angell-Petersen E, Madsen SJ, Spetalen S, Sun CH, Peng Q, Carper SW, Hirschberg H. Influence of light fluence rate on the effects of photodynamic therapy in an orthotopic rat glioma model. J Neurosurg 2006; 104: 109-117
28. Hunt MA, Bago AG, Neuwelt EA. Single-dose contrast agent for intraoperative MR imaging of intrinsic brain tumors by using ferumoxtran-10 AJNR. Am J Neuroradiol 2005; 26: 1084-1088
29. Veiseh O, Sun C, Gunn J, Kohler N, Gabikian P, Lee D, Bhattarai N, Ellenbogen R, Sze R, Hallahan A, Olson J, Zhang M. Optical and MRI multi-functional nanoprobe for targeting gliomas. Nano Lett 2005; 5: 1003-1008
30. Lyons SA, O'Neal J, Sontheimer H. Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin. Glia 2002; 39: 162-173
31. Tréhin R, Figueiredo J-L, Pittet 2 MJ, Weissleder R, Josephson L, Mahmood U. Fluorescent nanoparticle uptake for brain tumor visualization. Neoplasia 2006; 8: 302-311
32. Woodburn KW. Intracellular localization of the radiation enhancer motexafin gadolinium using interferometric Fourier fluorescence microscopy. J Pharmacol Exp Ther 2001; 297: 888-894
33. Viala J, Vanel D, Meingan P et al. Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: preliminary results in brain metastases. Radiology 1999; 212: 755-759
34. Mehta MP, Shapiro WR, Glantz MJ et al. Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol 2002; 20: 3445-3453
35. Mehta MP, Rodrigus P, Terhaard CH et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 2003; 21: 2529-2536
36. Meyers CA, Smith JA, Bezjak A et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol 2004; 22: 157-165
37. Rosenthal DI, Nurenberg P, Becerra CR et al. A Phase I single dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging. Clin Cancer Res 1999; 5: 739-745
38. Miller RA, Woodburn K, Fan Q, Renschler MF, Sessler JL, Koutcher JA. In vivo animal studies with gadolinium(III) texaphyrin as a radiation enhancer. Int J Radiation Oncology Biol Phys 1999; 45: 981-989